Amarin Corp plcAMRNEarnings & Financial Report
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
Revenue
$42.3M
Gross Profit
$16.3M
Operating Profit
$-25.2M
Net Profit
$-25.1M
Gross Margin
38.5%
Operating Margin
-59.5%
Net Margin
-59.4%
YoY Growth
-36.0%
EPS
$-0.06
Amarin Corp plc Q3 FY2024 Financial Summary
Amarin Corp plc reported revenue of $42.3M (down 36.0% YoY) for Q3 FY2024, with a net profit of $-25.1M (down 30.2% YoY) (-59.4% margin). Cost of goods sold was $26.0M, operating expenses totaled $41.4M.
Key Financial Metrics
| Total Revenue | $42.3M |
|---|---|
| Net Profit | $-25.1M |
| Gross Margin | 38.5% |
| Operating Margin | -59.5% |
| Report Period | Q3 FY2024 |
Amarin Corp plc Annual Revenue by Year
Amarin Corp plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $213.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $213.6M |
| 2024 | $228.6M |
| 2023 | $306.9M |
| 2022 | $369.2M |
Amarin Corp plc Quarterly Revenue & Net Profit History
Amarin Corp plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $45.1M | +7.0% | $-10.5M | -23.3% |
| Q4 FY2025 | $49.2M | -21.0% | $-1.2M | -2.5% |
| Q3 FY2025 | $49.7M | +17.4% | $-7.7M | -15.6% |
| Q2 FY2025 | $72.7M | +7.8% | $-14.1M | -19.4% |
| Q1 FY2025 | $42.0M | -25.7% | $-15.7M | -37.4% |
| Q4 FY2024 | $62.3M | -16.6% | $-48.6M | -78.0% |
| Q3 FY2024 | $42.3M | -36.0% | $-25.1M | -59.4% |
| Q2 FY2024 | $67.5M | -15.8% | $1.5M | 2.3% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $42.3M | $62.3M | $42.0M | $72.7M | $49.7M | $49.2M | $45.1M |
| YoY Growth | -15.8% | -36.0% | -16.6% | -25.7% | 7.8% | 17.4% | -21.0% | 7.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $799.9M | $750.6M | $685.3M | $655.7M | $670.1M | $659.8M | $670.8M | $645.8M |
| Liabilities | $248.0M | $219.2M | $199.2M | $182.0M | $205.2M | $200.9M | $211.5M | $196.4M |
| Equity | $551.9M | $531.4M | $486.2M | $473.7M | $464.9M | $458.9M | $459.3M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-2.7M | $-2.4M | $-13.3M | $-12.5M | $16.6M | $-12.7M | $15.3M |